Aidrivers founding member discusses AI, automation, and its challenges – Port Technology International

Senior Autonomy Scientist for AIDrivers and founding member, Dr Mohib, spoke in a recent interview about founding the artificial intelligence focused company and some of the upcoming projects that the company is working on.

Read the full interview here.

Dr Mohib worksclosely on the companys technical road map and assists team leads on the dayto day problem solving and in the integration of automation solution with existinginfrastructures.

He has a long educational history in the area of computer science and after graduating with a first-class honours BEng in computer system engineering from Brunel university he pursued his PhD research at UCL working novel generative agent based probabilistic estimation and update model for search and rescue application in wilderness using swarm of UAVs.

Given the fastpace of the area though Dr Mohib said that every day continues to be aneducation.

Thisfield is so fast-moving that I believe you can only stay in it with constantlyeducating yourself and keeping up to date with new technologies, new ideas andsolutions.

Structured education is great for specialisations and therefore is relevant up to a limit, but it can confine you. To excel, you need to be more open to understanding how things workwithout the limitations of application domain.

Hecredits Aidrivers with being a workplace where employees can continue a path ofpersonal growth without limitations as well as pursue entrepreneurial areas forproblem driven innovation.

Lookingahead to future developments Dr Mohib highlighted AI enabled autonomoussolutions with other automated solutions, all working seamlessly within theport industry.

For example, I want to see trucks and cranes working within one whole connected environment, He said.

Innovationlike this does not come without its challenges and Dr Mohib said that the mainhurdle will be the technology acceptance.

No matterhow much the technology improves, there will always be fear and nervousness ofthe use of Ai enabled algorithms in automated vehicles unless the trust isachieved. From ordinary persons perspective, one accident is too many when itcomes to automated vehicles even if the AI enabled autonomous system was not atfault.

Overall though it will be easier to integrate these kinds of levels of autonomy into industrial settings, compared with cities for example, because it is easier to plan, manage and enforce protocols.

Read the full interview here.

Go here to see the original:

Aidrivers founding member discusses AI, automation, and its challenges - Port Technology International

Todos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USA – BioSpace

REHOVOT, Israel, NEW YORK, NYand Shanghai, China, July 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd.(OTCQB: TOMDF), anin vitrodiagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimers disease, today announced that it has expanded its agreement with 3D Medicines Corporation for COVID-19 testing products.

Under the terms of the newly signed Medical Device Contract Manufacturing Agreement, Todos has been granted the exclusive right to seek out US Food & Drug Administration (FDA) Emergency Use Authorization (EUA) for 3D Meds SARS-CoV-19 and, as well as exclusive branding and distribution rights to 3D Meds qPCR test kits in the United States. 3D Med recently completed an expansion of its extraction reagent manufacturing capacity, by adding 1,000,000 extraction reagent production per week (~140,000 per day) that can be used towards deployment in the US.

The current daily testing volume in the United States is approximately 550,000 tests/day. The full deployment of 3D Meds additional extraction capacity would allow for an increase of approximately 25% in total US testing capacity per day. Todos has completed validation of 3D Meds qPCR kits and pre-loaded extraction reagents and automated machines at its partner CLIA/CAP certified lab Provista Diagnostics, Inc. in Alpharetta, GA.

Additionally, 3D Med has successfully validated pool testing at a ratio of 10:1, and Todos intends to complete pool testing validation here in the United States in the next several weeks so that it can seek US FDA EUA over the summer of 2020 and be ready to deploy pool testing broadly for Back to School and Return to Work testing, which Todos expects to ramp up significantly in the second half of Q3/2020. Pool testing of 10:1 would potentially increase capacity to a maximum of 1,400,000 tests per day.

It is now unequivocally clear that PCR testing is the gold standard in the United States for the foreseeable future, until new molecular technologies are able to reach the scale of current PCR testing, said Gerald Commissiong, President & CEO of Todos Medical. We are very pleased with the relationship we are building with 3D Med, especially as we see demand for extraction machines and reagents begin to really take off as smaller, independent labs begin to get involved in COVID-19 testing and they identify access to a stable supply of extraction reagents as the rate limiting step to market entry. We have started to ramp up sales, including a recent marquee sale of our ANDiS machines to the Cleveland Clinic, and we are now helping our clients get up and running so they can quickly expand their testing capacity. As we move into the next phase of growth for our emerging COVID-19 testing business, we are upselling our growing install base with Gnomegen qPCR kits and related materials so that Todos can compete effectively with competitors who tend to be focused on national and regional labs in the US. Our small and medium sized lab customer base greatly appreciates the availability of our extraction equipment and reagents.

Separately, Todos expanded its international distribution rights to 3D Meds COVID-19 testing products to include the United States, Israel, Singapore, Malaysia, Indonesia, Thailand, Myanmar, Vietnam, Philippine, Cambodia/Laos, Hong Kong, Japan, South Korea, Taiwan, India, United Kingdom, France, Sweden, Italy, Germany, Romania, Austria, Monaco, Switzerland, the Balkans, India, Gulf States, Dubai, UAE, Argentina, Aruba, Bahamas, Barbados, Belize, Bolivia (Plurinational State of), Mexico, Canada, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Martinique, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Suriname, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic of), Dominican Republic of Congo, Madagascar, Zimbabwe, Lesotho, Botswana, Angola, Zambia and South Africa.

For information related to Todos Medicals COVID-19 testing capabilities, please visit http://www.todoscovid.com

For testing and PPE inquiries, please email sales@todosmedical.com

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos, via its wholly-owned subsidiary Corona Diagnostics LLC, has formed strategic partnerships with Meridian Health, Moto-Para Foundation, Emerald Organic Products, Inc.s (OTC: EMOR) subsidiaries Carie.com and Bonsa Health to help deploy COVID-19 testing in the United States.

For more information, please visit https://www.todosmedical.com/

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Investor and Corporate Contact:

Kim Sutton Golodetz

LHA Investor Relations

Senior Vice President

(212) 838-3777

kgolodetz@lhai.com

Corporate Contact:

Daniel Hirsch

Todos Medical

(347) 699-0029

Dan.h@todosmedical.com

View original post here:

Todos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USA - BioSpace

Factory Automation Market Estimated to Expand at a Robust CAGR over 2020-2027 | ABB, Emerson Electric Company, Fanuc Corporation, GE Company – Cole of…

The Insight Partners provides you global research analysis on Factory Automation Market and forecast to 2027. The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Factory Automation market during the forecast period, i.e., 20202027.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Factory Automation market. The researcher provides an extensive analysis of the Factory Automation market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Get Sample Report of Factory Automation Market Report @ https://www.theinsightpartners.com/sample/TIPRE00009863/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Factory automation involves a set of technologies and control devices that enhance productivity, as well as the quality of products, while decrease the production cost. Factory automation regulates industrial processes and guarantees consistent, superior-quality results, which in turn has helped it to gain high demand in various industries for qualitative manufacturing. Moreover, it fulfils the demand of mass production in industries attributing to its features such as improved quality, minimal human intervention, and lesser labor expenses, which result in least overall operational cost.

The major factor that is boosting the growth of the factory automation market is the adoption of IoT and constant improvement in industrial robotics. In addition, demand for safety compliance automation products is further expected to provide significant growth opportunities for the factory automation market in the near future. However, significant capital investments for establishing an error-free automation system is anticipated to pose a big challenge in the growth of the factory automation market.

Major Key Players Covered In This Report: ABB Ltd., Emerson Electric Company, Fanuc Corporation, GE Company, Honeywell International Inc., Mitsubishi Electric Corporation, Omron Corporation, Robert Bosch GmbH, Rockwell Automation, Inc., Siemens AG

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Factory Automation market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Factory Automation market segments and regions.

The global factory automation market is segmented on the basis of type, product, technology, and industry vertical. Based on product, the market is segmented as sensors, controllers, industrial, robots, drives, others. On the basis of type, the market is segmented into programmable automation, fixed automation, integrated automation, and flexible automation. Further, the factory automation market based on technology is divided into programmable logic controller (PLC), distributed control system (DCS), supervisory control and data acquisition system (SCADA), human machine interface (HMI), Others. Based on industry vertical, the factory automation market is divided into automotive, food and beverage, oil and gas, manufacturing, mining, others.

The research on the Factory Automation market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Factory Automation market on the basis of end user, product type, application, and demography for the forecast period 20202027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Factory Automation market.

Factory Automation Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00009863/

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defence.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

Website: https://www.theinsightpartners.com/

Original post:

Factory Automation Market Estimated to Expand at a Robust CAGR over 2020-2027 | ABB, Emerson Electric Company, Fanuc Corporation, GE Company - Cole of...

Metrics and Automation Can Improve Federal Cybersecurity Measures – BroadbandBreakfast.com

July 9, 2020 Metrics are a new frontier for automating certain cybersecurity measurements, according to Mariam Baksh, a staff correspondent at Nextgov.

In a Thursday Nextgov webinar, moderated by Baksh, panelists discussed the benefits of utilizing automation to gather data for more informed metrics, in order to ultimately solve pressing cybersecurity issues in both the federal and private sector.

Its important to remember when we say metrics, we just mean measurements, said Brandon Valeriano, senior advisor of the Cyberspace Solarium Commission.

Automation and metrics are currently being utilized by the Continuous Diagnostics and Mitigation Program, a leading effort to reduce cyber risk and provide asset visibility to the federal government.

By distributing automated tools to federal agencies, their ability to monitor and manage the threat of cyber vulnerabilities is strengthened.

The goal of CDM is to improve the federal governments respective security posture, said program manager Kevin Cox.

Agencies are not aware of their attack surface, Cox said, referring to all of the places an advisory is able to exploit a network.

When the CDM program was utilized, researchers found that agencies have 75 percent more assets than they were manually reported, Cox said.

The objectives of the program are to reduce agencies threat surface, increase visibility into the federal cybersecurity posture and improve federal cybersecurity response capabilities.

Valeriano, who Baksh mentioned had more experience in the private sector than his fellow panelists, spoke of utilizing metrics and automation to solve an alternative problem.

Were generally collecting data on security risks for no real purpose of analysis, Valeriano said. We only know about what were already looking for.

Valeriano called for utilizing metrics to develop a better situational hyper-awareness, so eventually attacks could be predicted and mitigated.

Other panelists reported that they are not doing the type of work that Valeriano described, revealing a division in development between segments of the private and public sector.

Automation is the way to go, said Vijay DSouza, director of the information technology and cybersecurity team at the Government Accountability Office. The more tools you have to handle the vast amounts of data were dealing with the better.

However, automation may not catch major threats, such as attackers going for harder to exploit targets, DSouza said.

To solve this, a marriage of artificial intelligence and human intelligence is ideal, he said.

Visit link:

Metrics and Automation Can Improve Federal Cybersecurity Measures - BroadbandBreakfast.com

COVID-19 Impact on Global Automation Position Sensor Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast Outlook 2026 -…

***Updated Free Sample Report Is Ready To Dispatch

Summary: Automation Position Sensor Market

This report denotes a committed and all-inclusive assessment of the present comparisons documented in the Automation Position Sensor Market. It delivers an articulate brief, which gets in sync the viewpoint of the report in the Automation Position Sensor Market, its efficacies, as well as the dealings that are in employment. The Automation Position Sensor Markets experience is prepared by the specialists examination of the market circumstance, and the significant industry developments in the remarkable regions of the market share. Likewise, the Automation Position Sensor Market report makes it simple to advance to the working expenditure limitations of the product and the succeeding pressures encountered by the connections in the Automation Position Sensor Market. The international Automation Position Sensor Market report presents a comprehensive evidence flow of the different inspirations that are intensifying the Automation Position Sensor Market. The report facilitates the reporting of the market state and the forecast period up to 2026.

Free Sample Report PDF: COVID-19 Impact on Global Automation Position Sensor Market Outlook @

https://www.wiseguyreports.com/sample-request/5468592-global-industrial-automation-position-sensor-market-research-report-2020?utm_medium=Jiten-10.7&utm_source=PR

Understanding the segments helps in identifying the importance of different factors that aid the

Drivers and Risks

The report also calls to the focus of work tendencies inside the market as well as the appraisals in addition to assembling comprehension into the operative traces on behalf of the Automation Position Sensor Market. A buildup of potential extension stages, forces, and estimations are also revealed to get a much-adjusted explanation of the Automation Position Sensor Markets progress.

Regional Description

The region-wise estimation of the Automation Position Sensor Market has a renowned intent of checking the market constituent of expansion and classifying the forecasts regarding progress, which are apparent through the known regions. The report also evaluates the regions such as Europe, Asia Pacific, Latin America, North America, and the MEA with the reexamination of the Automation Position Sensor Market for the approaching years. The hesitations decelerating the Automation Position Sensor Market predispositions are arranged with all these regions to transmit into line the structures of the latest trends, perspective, and settings validated in the appraisal period concluding in 2026. The investigation of the Automation Position Sensor Market observes many regions on an international stage, where the greatest transactions have implications concentrated on positive returns through alliances in only specific regions.

View Complete Report / Any Query @

https://www.wiseguyreports.com/reports/5468592-global-industrial-automation-position-sensor-market-research-report-2020?utm_medium=Jiten-10.7&utm_source=PR

Key Market Trends | Growth | Share | Sale | Revenue | Manufactures | Technology Component

Method of Research

The investigation of the market comprises of the methods of its primary pressures, areas, and selections. Also, the establishments, using the SWOT based on which the review is made adroit at presenting careful opinions about the Automation Position Sensor Market. To provide widespread inspection, the Automation Position Sensor Market is divided on the basis of a coalition of forces at work that is reviewed in Porters Five Force Model in the period ahead.

Key Players

The report adds the concentration on the markets experience along with the tendencies mutable in the purview. The report centres on the latest sellers in the market segments, which displays the chief participants input to the Automation Position Sensor Market.

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

What are the key segments in the market?

Which market dynamics affect the business?

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Table of Content: Covid-19 Impact On Automation Position Sensor Market

1 Study Coverage

2 Executive Summary

3 Breakdown Data by Manufacturers

4 Breakdown Data by Type

5 Breakdown Data by Application

11 Company Profiles

12 Future Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

14 Value Chain and Sales Channels Analysis

15 Research Findings and Conclusion

16 Appendix

Continued

Download Free Sample Copy @

https://www.wiseguyreports.com/sample-request/5468592-global-industrial-automation-position-sensor-market-research-report-2020?utm_medium=Jiten-10.7&utm_source=PR

NOTE : Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Wise Guy Reports Is Part of the Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data for Industries and Governments Around the Globe. Wise Guy Reports Features an Exhaustive List of Market Research Reports from Hundreds of Publishers Worldwide. We Boast a Database Spanning Virtually Every Market Category and an Even More Comprehensive Collection of Market Research Reports Under These Categories and Sub-Categories.

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

[emailprotected]

http://Www.Wiseguyreports.Com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Here is the original post:

COVID-19 Impact on Global Automation Position Sensor Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast Outlook 2026 -...

Intel’s automated inventory planning: How it swapped ‘rule-of-thumb’ for algorithms – Supply Chain Dive

Dive Brief:

The paper defines the savings as the "first-year reduction in inventory carrying cost."

The "multiechelon inventory optimization" model turned an inventory management process that previously relied on "rule-of-thumb heuristics and spreadsheets" into one where planners accept an algorithm's automatically generated inventory targets 99.5% of the time, the researchers said.

As the researchers point out, the importance of getting inventory levels right was something Intel, a company that has been manufacturing for decades, understood quite well.

"Since Intels first device rolled off the manufacturing line, holding too much inventory has wasted capacity and holding too little has risked revenue," the researchers wrote. The effort got some push back in the early days with comments suggesting it wouldn't work or the current method was functioning fine. But when a former factory manager was appointed as the VP of supply chain, "he felt there must be a better and more scientific way to set inventory targets than just planner rule-of-thumb estimates applied across all products," the paper reads.

The automation of the process has allowed planners to focus on more complicated inventory issues within the company, the paper said.

"All facets of calculating the inventory targets (e.g., processing data inputs, calculating targets, publishing summary statistics) were automated, freeing planners to handle only the exceptions the truly problematic SKUs on allocation or newly launched in uncertain markets," the researchers wrote.

Intel began piloting the new inventory model in 2005 with its boxed CPU channel, which sells microprocessors in retail-branded boxes through distributors and local computer manufacturers. It resulted in an 11% reduction in inventory investment while total demand was satisfied on time more than 90% of the time, the paper said.

But in the pilot, workers would still manually override the algorithm about 50% of the time. The researchers tweaked the algorithm to improve its fit before rolling it out more widely across the company.

The pilot only ran on some of the SKUs within the boxed CPU business, which provided the researchers with a control. The new method satisfied demand on time at a higher level than the old method while keeping lower inventory levels. Notably, the SKUs using the new model also "avoided the wild fluctuations in inventory that the control group experienced during the turbulent markets of the Great Recession," the paper said.

In 2011, Intel began rolling out the model to its vendor-managed inventory, which was a year-long effort.

As for forecasting the demand for new products, Intel began mapping products to tie current items to its most-similar predecessor. The company relied on a number of variables to make the comparison including price, division code, market segment and microprocessor brand. The company only uses a product's data to forecast demand if it has 22 weeks of demand data. If it doesn't, then it forecasts the demand using historical data from other products.

Planners were able to override the algorithm's suggestions throughout the pilot, but the frequency of this trended down throughout the project as the model improved.

This story was first published in our weekly newsletter, Supply Chain Dive: Operations. Sign up here.

Read more here:

Intel's automated inventory planning: How it swapped 'rule-of-thumb' for algorithms - Supply Chain Dive

AR Automation Software Market (COVID-19 UPDATED) Growing Trend and Regional Analysis by: Sage Intacct, SAP, Invoiced, Accounting Seed – 3rd Watch News

AR Automation Software Market research report displays the market size, share, status, production, cost analysis, and market value with the forecast period 2019-2024. The overall analysis of Advanced AR Automation Software Market covers an overview of the industry policies. The report also details the information about the top key players, sales, revenue, future trends, research findings, and opportunities. The prime objective of this report is to help the user understand the AR Automation Software market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing.

A thorough observe of the aggressive landscape of the AR Automation Software Markethas beenprovidingsupplying insights into the organization profiles, monetary status, current traits, mergers, andacquisitions, and the SWOT evaluation. It presents a sophisticated view of the classifications, programs,segmentations, specs and many greater for AR Automation Software Market. This marketplace research is an intelligence document with meticulous efforts undertaken to take a look at the rightandvaluable statistics. Regulatory eventualities that have an effect onvariousselections within the AR Automation Software Marketare given a keen observation and were explained.

Get Sample Copy of this Report athttps://www.reportsintellect.com/sample-request/778231

Some of the leading market players include:Sage Intacct, SAP, Invoiced, Accounting Seed

Reports Intellect projects AR Automation Software Market based on elite players, present, past and futuristic data which will offer as a profitable guide for all AR Automation Software Market competitors. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Segmentation by Type:

Cloud BasedWeb Based

Segmentation by application:

Large EnterprisesSMEs

Instant Discount Now athttps://www.reportsintellect.com/discount-request/778231?ata

Table of Contents

2019-2024 Global AR Automation Software Market Report

1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered

2 Executive Summary2.1 World Market Overview2.1.1 Global AR Automation Software Market Size 2014-20242.1.2 AR Automation Software Market Size CAGR by Region2.2 AR Automation Software Segment by Type2.2.1 Cloud Based2.2.2 Cloud Based2.3 AR Automation Software Market Size by Type2.3.1 Global AR Automation Software Market Size Market Share by Type (2014-2019)2.3.2 Global AR Automation Software Market Size Growth Rate by Type (2014-2019)2.4 AR Automation Software Segment by Application2.4.1 Large Enterprises2.4.2 SMEs2.5 AR Automation Software Market Size by Application2.5.1 Global AR Automation Software Market Size Market Share by Application (2014-2019)2.5.2 Global AR Automation Software Market Size Growth Rate by Application (2014-2019)

3 Global AR Automation Software by Players

Continued.

Reasons to buy this report:

Contact Us:

[emailprotected]PH + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Link:

AR Automation Software Market (COVID-19 UPDATED) Growing Trend and Regional Analysis by: Sage Intacct, SAP, Invoiced, Accounting Seed - 3rd Watch News

Global CLINICAL DIAGNOSTICS AUTOMATION Market 2020 : Worldwide Overview by Industry Size and Share, Future Trends, Growth Factors and Leading Players…

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global CLINICAL DIAGNOSTICS AUTOMATION Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global CLINICAL DIAGNOSTICS AUTOMATION market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/35966

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional CLINICAL DIAGNOSTICS AUTOMATIONgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global CLINICAL DIAGNOSTICS AUTOMATION market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of CLINICAL DIAGNOSTICS AUTOMATION industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of CLINICAL DIAGNOSTICS AUTOMATION in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global CLINICAL DIAGNOSTICS AUTOMATION market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Abaxis

Abbott Diagnostics

Beckman Coulter

Becton, Dickinson and Company

BioMerieux SA

Bio-Rad Laboratories

Diagnostica Stago

Ortho Clinical Diagnostics

PerkinElmer

Siemens Healthcare Diagnostics

Sysmex America

Tecan Group

The ELITechGroup

Thermo Fisher Scientific

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Modular Automation

Total Lab Automation

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of CLINICAL DIAGNOSTICS AUTOMATION for each application, including

Clinical Diagnostics

Drug Discovery

Proteomics Solutions

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/35966

Major Point of TOC:

Chapter One: CLINICAL DIAGNOSTICS AUTOMATION Market Overview

Chapter Two: CLINICAL DIAGNOSTICS AUTOMATION Market Segment Analysis by Player

Chapter Three: CLINICAL DIAGNOSTICS AUTOMATION Market Segment Analysis by Type

Chapter Four: CLINICAL DIAGNOSTICS AUTOMATION Market Segment Analysis by Application

Chapter Five: CLINICAL DIAGNOSTICS AUTOMATION Market Segment Analysis by Sales Channel

Chapter Six: CLINICAL DIAGNOSTICS AUTOMATION Market Segment Analysis by Region

Chapter Seven: Profile of Leading CLINICAL DIAGNOSTICS AUTOMATION Players

Chapter Eight: Upstream and Downstream Analysis of CLINICAL DIAGNOSTICS AUTOMATION

Chapter Nine: Development Trend of CLINICAL DIAGNOSTICS AUTOMATION (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/35966

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

Originally posted here:

Global CLINICAL DIAGNOSTICS AUTOMATION Market 2020 : Worldwide Overview by Industry Size and Share, Future Trends, Growth Factors and Leading Players...

Impact Of Covid-19 Outbreak On Oil and Gas Process Automation and Instrumentation Market 2020 Trends, Growth Opportunities, Demand, Application, Top…

The globalOil and Gas Process Automation and Instrumentation Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Oil and Gas Process Automation and Instrumentation market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Oil and Gas Process Automation and Instrumentation market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Oil and Gas Process Automation and Instrumentation market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Oil and Gas Process Automation and Instrumentation market.

Leading players of the global Oil and Gas Process Automation and Instrumentation market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Oil and Gas Process Automation and Instrumentation market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Oil and Gas Process Automation and Instrumentation market. It also provides useful recommendations for new as well as established players of the global Oil and Gas Process Automation and Instrumentation market.

Request sample copy of this report:https://www.reporthive.com/request_sample/2367692

Major Players:

ABBSiemensSchneider ElectricRockwell AutomationGeneral Electric Corporation

Segmentation by Product:

DCS (Distributed Control System)PLC (Programmable Logic Controller)SCADA (Supervisory Control And Data Acquisition)ACS (Automation And Control System)MES (Manufacturing Execution System)/SIS (Safety Instrumented Systems)

Segmentation by Application:

Oil& GasFood& BeveragesChemicalsPharmaceuticalsWater& Wastewater/Metals& Mining/Energy& Power/Pulp & Paper

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

Table of Contents

Report Overview:It includes major players of the global Oil and Gas Process Automation and Instrumentation market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Oil and Gas Process Automation and Instrumentation market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Oil and Gas Process Automation and Instrumentation market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Oil and Gas Process Automation and Instrumentation market by application, it gives a study on the consumption in the global Oil and Gas Process Automation and Instrumentation market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Oil and Gas Process Automation and Instrumentation market are profiled in this section. The analysts have provided information about their recent developments in the global Oil and Gas Process Automation and Instrumentation market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Oil and Gas Process Automation and Instrumentation market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Oil and Gas Process Automation and Instrumentation market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Oil and Gas Process Automation and Instrumentation market.

Key Findings:This section gives a quick look at important findings of the research study.

Request for Customization:https://www.reporthive.com/request_customization/2367692

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Read the original here:

Impact Of Covid-19 Outbreak On Oil and Gas Process Automation and Instrumentation Market 2020 Trends, Growth Opportunities, Demand, Application, Top...

COS Systems Ready to Automate Open Access Networks as a Nokia Connected Partner – Broadband Communities

UMEA, SWEDEN COS Systems is specializing in software to operate broadband networks open for multiple providers delivering services on a shared infrastructure. Nokia is a global leader in fixed and wireless networks and networking technologies for open network architectures, software defined networking and network slicing. After recent integration work the cooperation between the companies is now formalized as COS Systems becomes a Nokia Fixed Networks OSS Connected Partner.

With new types of services emerging, such as telehealth, internet of things and smart services, it is becoming increasingly important to have a network open for multiple providers. Instead of building a proprietary network and trying to produce all the services current and future customers will need, it is attractive to provide a robust infrastructure and then open it up to multiple specialized providers on a wholesale basis.

In 2014 when we established COS Systems in the United States, Open Access was almost unheard of, but in just a few years this has changed dramatically. Especially municipalities are realizing that their best choice is not to become a provider of telecommunications services, but to ensure that this critical infrastructure is in place, just as with other utilities such as roads, water and electricity, says Bjorn Wannman, sales manager at COS Systems.

True Open Access Networks

With COS Systems heritage from Sweden, where their BSS/OSS platform COS Business Engine is used to operate more than a hundred municipal and utility fiber networks, this is not something new. For over a decade COS has enabled True Open Access Networks, where subscribers can access an online marketplace and choose freely between any type of services provided by many competing service providers. The competitive nature of the marketplace brings service innovation, increased quality, and lower prices. This is also where the partnership with Nokia comes into play. For a network deployed using Nokia Fixed Access equipment COS will be able to fully automate the subscribers interaction with the marketplace. As subscribers are managing their services on the marketplace, COS Business Engine will instruct Nokias management and control platform to instantly perform desired changes in the network.

With the tools to simplify business and network operations, COS Systems is able to uniquely meet operator needs for network automation. With this cooperation, operators - regardless of whether they are new or existing players in the market - can easily automate the delivery of high-speed broadband services to their residential and enterprise customers, says Bassam El-Zakhem, vice president, Fixed Networks Americas at Nokia.

Nokias OSS Connected Partner Program

Were excited to be part of Nokias OSS Connected Partner Program. They share our visions about open networks and what we see today is just the beginnings of what will come. Working together with a global leader such as Nokia on current and emerging Software Defined Networking and network slicing technology is thrilling. Network owners and operators working with us will know they are choosing an open and future proof solution, says Isak Finer, CMO and VP North America at COS Systems.

COS Systems has unique understanding and experience in the open type of networks that are becoming increasingly important. By combining the Nokia AMS and Altiplano management and control platforms with the COS Business Engine, operators can more effectively keep up with rapidly changing customer demands. Were happy to welcome COS Systems as OSS Connected Partners, says Bassam El-Zakhem, vice president, Fixed Networks Americas at Nokia.

Read this article:

COS Systems Ready to Automate Open Access Networks as a Nokia Connected Partner - Broadband Communities

Global Sales of Oil and Gas Terminal Automation Market to Follow a Downward Trend Post 2026, with Co – PharmiWeb.com

VALLEY COTTAGE, N.Y. The report Oil and Gas Terminal Automation Market: Global Industry Analysis and Opportunity Assessment, 20162026 offers a 10-year forecast for the global oil and gas terminal automation market for the period of 20162026. The report studies the oil and gas terminal automation market across six key regions of the globe, including North America, Latin America, Asia Pacific excl. Japan, Middle East & Africa, Europe and Japan. The report covers key factors driving the growth of the market, trends and developments shaping the dynamics of the market and other insights across key segments.

Report description

This Future Market Insights report examines the global oil and gas terminal automation market for the period 20162026 in terms of value. The primary objective of the report is to offer updates on developments in the oil & gas terminal automation market and quantification of revenue generation from oil and gas terminal automation across various categories and country/ regional market segments.

For more insights into the market, request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-197

On the basis of categories, the global oil and gas terminal automation market is segmented into:

The report starts with the oil and gas terminal automation market overview and provides market definition and overview of category based segments for global oil and gas terminal automation market. The sections that follow include market analysis and forecast, by category and by region, country level. All the above sections evaluate the market on the basis of various factors affecting the market, covering present scenario and future prospects. For market data analysis, the report considers 2015 as the base year, with market numbers estimated for 2016 and the forecast made for 20162024.

In the final section of the report, a competitive landscape has been included to provide a dashboard view of key companies operating in the global oil and gas terminal automation market. This section is primarily designed to provide clients with an objective and comparative assessment of key providers specific to a market segment in the global oil and gas terminal automation market. The section also includes market strategies and SWOT analysis of the main players operational in the global oil and gas terminal automation market.

Research methodology

To quantify the market size, an elaborate research methodology comprising in-depth secondary research and number of primary interviews have been done followed by triangulation of the data thus gathered. Further, data inputs such as market split by categories, and qualitative inputs from industry experts have been taken into consideration before concluding the market estimates. Each region based section highlights the oil and gas terminal automation market based on different categories in that region. To give a brief idea about revenue opportunities from various services and region/ country, the report also provides absolute $ opportunity and total incremental opportunity for each segment over the forecast period.

Request for covid19 Impact Analysis @ https://www.futuremarketinsights.com/covid19/rep-gb-197

The market size estimation is carried out through multiple top-down and bottom-up approaches. Crude oil production data historical and forecast, is benchmarked to identify relative shares in the market and the market data range, thus received, has been validated by primary resources. Moreover, Infrastructure investments, indicative share of automation in overall investment and upcoming terminals related data has been considered to determine the respective market share and corresponding growth rates.

In the final section of the report, a competitive landscape has been included to provide report audiences with a dashboard view. Detailed profiles of oil and gas terminal automation solution providers are also included within the scope of the report in order to help evaluate strategies, key recent developments in the global market.

Original post:

Global Sales of Oil and Gas Terminal Automation Market to Follow a Downward Trend Post 2026, with Co - PharmiWeb.com

Bogot returns to strict quarantine based on rotating localities as of July 13 – The City Paper Bogot

Bogot Mayor Claudia Lpez placed the Colombian capital under Orange Alert given the spread of coronavirus and announced that the citys 10 million inhabitants will return to strict quarantine based on localities, divided in 3 groups. The strict quarantine will be enforced by an additional 850 members of the National Police. A liquor sale ban is in effect in all localities during the strict quarantine.

Lockdown starts Monday, July 13, and ends August 23.

Group 1: Starts July 13 and ends July 26. Localities: Ciudad Bolvar, San Cristbal, Rafael Uribe Uribe, Chapinero, Santafe, Usme, Los Mrtires and Tunjuelito.

Group 2: Starts July 27 and ends August 9. Localities: Bosa, Kennedy, Puente Aranda and Fontibn.

Group 3: Starts August 10 and ends August 23. Localities: Suba, Engativ and Barrios Unidos.

During each of the respective 14 days, localities will have total restriction on mobility and all shops must close, except supermarkets and pharmacies for basic necessities.

All residents must be inside their homes from 8 pm to 5 am.

Essential errands can only be done by one member of the household from 5 am to 7 pm.

Those exempt from mobility restrictions are health workers and elderly care personnel.

The strict quarantine was presented to the government of President Ivn Duque and approved for the district capital. Mayor Lpez also announced during a virtual press conference that 550,000 poor and vulnerable families will receive money from Bogot Solidaria en Casa in order to guarantee a basic income during the peak of the pandemic. Families in need will receive $240,000 pesos and resources that will be covered jointly between Bogot and Nation. The district will also deliver 150,000 food markets. Families in these localities who need to access these benefits and are not registered in the database can apply with the Bogot Caregiver App.

Together we are going to take care of ourselves to pass the peak of contagion. We are no longer going to postpone it, we are going to face it and we are going to achieve it, it is at this moment that we need the unity of all citizens, said Lpez.

Read more:

Bogot returns to strict quarantine based on rotating localities as of July 13 - The City Paper Bogot

3D Printed Medicine Uses Fish Gelatin to Deliver Cancer Treatment – 3DPrint.com

Japanese researchers Jin Liu, Tatsuaki Tagami, and Tetsuya Ozeki have completed a recent study in nanomedicine, releasing their findings in Fabrication of 3D Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin. Experimenting with a new drug delivery system, the authors report on new potential for patient-specific cancer treatment.

The study of materials science continues to expand in a wide range of applications; however, bioprinting is one of the most exciting techniques as tissue engineering is expected to lead to the fabrication of human organs in the next decade or so. Such research has also proven that bioprinting may yield much more powerful drug delivery whether in using hybrid systems, multi-drug delivery systems, or improved scaffolds.

Here, the materials chosen for drug delivery are more unique as the researchers combined printer ink with semi-synthesized fish gelatin methacryloyl (F-GelMA)a cold fish gelatin derivative.

In providing aggressive cancer treatment to patients, the use of doxorubicin (DOX) is common as an anti-carcinogen for the treatment of the following diseases:

DOX may also cause serious cardiotoxicity, however, despite its use as a broad-spectrum drug. As a solution, PEGylated liposomal DOX, Doxilhas been in use for treatment of cancer with much lower cardiotoxity. The nanomedicine has also been approved by the FDA, and is used for targeting local tumors; for instance, this type of drug delivery system could be suitable for treating a brain tumor.

PEGylating liposomes can prolong their circulation time in blood, resulting in their passive accumulation in cancer tissue, called the enhanced permeability and retention effect, state the authors.

Using a 3D bioprinter, the authors developed liposomal patches to be directly implanted into cancerous cells.

(a) Synthesis of fish gelatin methacryloyl (F-GelMA). (b) Hybrid gel of cross-linked F-GelMA and carboxymethyl cellulose sodium (CMC) containing PEGylated liposome. The reaction scheme was prepared in previous studies

We used a hydrogel containing semi-synthetic fish-gelatin polymer (fish gelatin methacryloyl, F-GelMA) to entrap DOX-loaded PEGylated liposomes. Fish gelatin is inexpensive and faces few personal or religious restrictions, stated the authors.

Fish gelatin has not been used widely in bioprinting, however, due to low viscosity and rapid polymerization. To solve that problem, the authors created a bioink composite with elevated viscosity.

Viscous properties of drug formulations used as printer inks. (a) The appearance of F-GelMA hydrogels containing different concentrations of CMC. (b) The viscosity profiles of F-GelMA hydrogels containing different concentrations of CMC. The data represent the mean SD (n = 3).

And while hydrogels are generally attractive for use due to their ability to swell, for this study, the researchers fabricated a variety of different materialswith the combination of 10% F-GelMA and 7% carboxymethyl cellulose sodium (a thickening agent) showing the highest swelling ratio.

Swelling properties of hydrogels after photopolymerization. (a) Swelling ratio of different concentrations of F-GelMA. (b) Swelling ratio of mixed hydrogel (10% F-GelMA with different concentrations of CMC). The data represent the mean SD (n = 3).

Design of the different 3D geometries: (a) cylinder, (b) torus, and (c) gridlines.

Patches were printed in three different sample shapes, using a CELLINK bioprinter syringe as the authors tested drug release potential in vivo. Realizing that surface area, crosslinks density, temperature, and shaker speed would play a role, the team relied on a larger surface volume for more rapid release of drugs.

Printing conditions of patches.

While experimenting with the torus, gridline, and cylindrical sample patches, the researchers observed gridline-style patches as offering the greatest potential for sustained release.

Drug release profiles of liposomal doxorubicin (DOX). (a) Influence of shape on drug release. The UV exposure time was set to 1 min. (b) Influence of UV exposure time on drug release. The gridline object was used for this experiment. The data represent the mean SD (n = 3).

These results indicate that CMC is useful for adjusting the properties of printer ink and is a useful and safe pharmaceutical excipient in drug formulations. We also showed that drug release from 3D-printed patches was dependent on the patch shapes and UV exposure time, and that drug release can be controlled. Taken together, the present results provide useful information for the preparation of 3D printed objects containing liposomes and other nanoparticle-based nanomedicines, concluded the authors.

Continued here:

3D Printed Medicine Uses Fish Gelatin to Deliver Cancer Treatment - 3DPrint.com

Class of 2017’s Dr. Jawan Gorgis is Family Medicine Resident of the Year – The South End

Wayne State University School of Medicine alumna Jawan Gorgis, M.D., was named by the Michigan Academy of Family Physicians as one of only two Michigan Family Medicine Residents of the Year.

Dr. Gorgis who graduated from the School of Medicine in 2017, is a resident in Beaumont Health of Troys Family Medicine residency program.

Associate Dean of Student Affairs and Career Development Margit Chadwell, M.D., wrote Dr. Gorgiss recommendation letter for the Beaumont residency program.

I (had) the pleasure of getting to know Jawan through her engagement with our Family Medicine Interest Group, where I serve as the faculty advisor. Jawan is inquisitive and resourceful, and has actively explored family medicine as a specialty choice. I have been impressed by her professional and pleasant demeanor, and her enthusiasm, Dr. Chadwell wrote.

Dr. Gorgis will receive the award during the virtual Academy Awards celebration Aug. 8, immediately following thevirtual MAFP Annual Meeting.

The Michigan Family Medicine Resident of the Yearaward recognizes a Family Medicine resident (PGY-1, PGY-2 or PGY-3) who exhibits qualities of exemplary patient care, demonstrates leadership among colleagues, displays a commitment to the community at large and is dedicated to the specialty through involvement in the MAFP and AAFP, service to the residency program, and/or other Family Medicine organizations.

As a student, Dr. Gorgis served as the education and training director for Street Medicine Detroit, coordinating and providing medical assistance to the citys most disadvantaged population. She was elected the schools national representative to the American Medical Association, and participated in the comprehensive Fabric of Society and Medical Political Action Committee Co-Curricular program, volunteering 150 hours in multiple community organizations, clinics and lobbying efforts. She obtained certification as an HIV counselor. She also was involved with multiple research studies resulting in a publication on her diabetes project. Her work with Street Medicine Detroit resulted in two posters she presented at national conferences.

Visit link:

Class of 2017's Dr. Jawan Gorgis is Family Medicine Resident of the Year - The South End

WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls – World Health Organization

Seventy-three countries have warned that they are at risk of stock-outs of antiretroviral (ARV) medicines as a result of the COVID-19 pandemic, according to a new WHO survey conducted ahead of the International AIDS Societys biannual conference. Twenty-four countries reported having either a critically low stock of ARVs or disruptions in the supply of these life-saving medicines.

The survey follows a modelling exercise convened by WHO and UNAIDS in May which forecasted that a six-month disruption in access to ARVs could lead to a doubling in AIDS-related deaths in sub-Saharan Africa in 2020 alone.

In 2019, an estimated 8.3 million people were benefiting from ARVs in the 24 countries now experiencing supply shortages. This represents about one third (33%) of all people taking HIV treatment globally. While there is no cure for HIV, ARVs can control the virus and prevent onward sexual transmission to other people.

A failure of suppliers to deliver ARVs on time and a shut-down of land and air transport services, coupled with limited access to health services within countries as a result of the pandemic, were among the causes cited for the disruptions in the survey.

The findings of this survey are deeply concerning, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. Countries and their development partners must do all they can to ensure that people who need HIV treatment continue to access it. We cannot let the COVID-19 pandemic undo the hard-won gains in the global response to this disease.

According to data released today from UNAIDS and WHO, new HIV infections fell by 39% between 2000 and 2019. HIV-related deaths fell by 51% over the same time period, and some 15 million lives were saved through the use of antiretroviral therapy.

However, progresstowards global targets is stalling. Over the last two years, the annual number of new HIV infections has plateaued at 1.7 million and there was only a modest reduction in HIV-related death, from 730 000 in 2018 to 690 000 in 2019. Despite steady advances in scaling up treatment coverage with more than 25 million people in need of ARVs receiving them in 2019 key 2020 global targets will be missed.

HIV prevention and testing services are not reaching the groups that need them most. Improved targeting of proven prevention and testing services will be critical to reinvigorate theglobal response to HIV.

COVID-19 risks exacerbating the situation. WHO recently developed guidance for countries on how to safely maintain access to essential health services during the pandemic, including forall people living with or affected by HIV. The guidance encourages countries to limit disruptions in access to HIV treatment through multi-month dispensing, a policy whereby medicines are prescribed for longer periods of time up to six months. To date, 129 countries have adopted this policy.

Countries are also mitigating the impact of the disruptions by working to maintain flights and supply chains, engaging communities in the delivery of HIV medicines, and working with manufacturers to overcome logistics challenges.

At the IAS conference, WHO will highlight how global progress in reducing HIV-related deaths can be accelerated by stepping up support and services for populations disproportionately impacted by the epidemic, including young children. In 2019, there were an estimated 95 000 HIV-related deaths and 150 000 new infections among children. Only about half (53%) of children in need of antiretroviral therapy were receiving it. A lack of optimal medicines with suitable pediatric formulations has been a longstanding barrier to improving health outcomes for children living with HIV.

Last month, WHO welcomed a decision by the U.S. Food and Drug Administration to approve a new 5mg formulation of dolutegravir (DTG) for infants and children older than 4 weeks and weighing more than 3 kg. This decision will ensure that all children have rapid access to an optimal drug that, to date, has only been available for adults, adolescents and older children. WHO is committed to fast-tracking the prequalification of DTG as a generic drug so that it can be used as soon as possible by countries to save lives.

Through a collaboration of multiple partners, we are likely to see generic versions of dolutegravir for children by early 2021, allowing for a rapid reduction in the cost of this medicine, said Dr Meg Doherty, Director of the Department of Global HIV, Hepatitis and STI Programmes at WHO. This will give us another new tool to reach children living with HIV and keep them alive and healthy.

Many HIV-related deaths result from infections that take advantage of an individuals weakened immune system. These include bacterial infections, such as tuberculosis, viral infections likehepatitis and COVID-19, parasitic infections such as toxoplasmosis and fungal infections, including histoplasmosis.

Today, WHO is releasing new guidelines for the diagnosis and management of histoplasmosis, among people living with HIV. Histoplasmosis is highly prevalent in the WHO Region of theAmericas, where as many as 15 600 new cases and 4500 deaths are reported each year among people living with HIV. Many of these deaths could be prevented through timely diagnosis and treatment of the disease.

In recent years, the development of highly sensitive diagnostic tests has allowed for a rapid and accurate confirmation of histoplasmosis and earlier initiation of treatment. However, innovative diagnostics and optimal treatments for this disease are not yet widely available in resource-limited settings.

See the original post here:

WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls - World Health Organization

American College of Lifestyle Medicine Launches Campaign to Promote Treatment and Reversal of Chronic Disease with Lifestyle Medicine – PRNewswire

The convergence of the COVID-19 pandemic and racial unrest has been a wake-up call on the state of our individual and collective health, highlighting health disparities and faults in our health care system and medical schools.Our nation's lack of health has left us blindsided and vulnerable to the ravages of COVID-19, particularly in minority and underservedcommunities.

Chronic disease is the leading cause of death and disability in the U.S., having reached epidemic proportions. Sixty percent of American adults now live with at least one chronic condition, while 42 percent have more than one. African American adults in particular are more likely to have high blood pressure and diabetes, in part due to the chronic, toxic stress associated with racism. Chronic disease now accounts for as much as 86 percent of all health care expenditures. Yet our health care and medical education systems focus on chronic disease management rather than the health restoration provided by addressing its root-causes. Despite most chronic diseases being caused by unhealthy lifestyle behaviors, training in the pillars of Lifestyle Medicine has been virtually non-existent in medical schools.

Lifestyle Medicine is the use of a whole food, plant-predominant dietary lifestyle, regular physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connection as a primary therapeutic modality for treatment and reversal of chronic disease.

ACLM President Dr. Dexter Shurney and other Lifestyle Medicine experts are available for media interviews and background. See our media kit: https://bit.ly/2O7loms.

Topics ACLM experts can be resources for include:

ACLM provides live and online CME-accredited events and courses for physicians and allied health professionals across the continuum of medical education, as well as certification, clinical practice tools, patient education resources, economic research, networking opportunities and advocacy. Board certification has been available since 2017.

SOURCE American College of Lifestyle Medicine

http://www.lifestylemedicine.org

Read more from the original source:

American College of Lifestyle Medicine Launches Campaign to Promote Treatment and Reversal of Chronic Disease with Lifestyle Medicine - PRNewswire

Explained: What works in Covid-19 treatment – The Indian Express

Written by Dr Satchit Balsari, Dr Zarir Udwadia | New Delhi | Updated: July 11, 2020 11:09:48 am

Like a wedding guest piling food from a buffet onto their plate until there is no place left, doctors have been prescribing fistfuls of drugs when attempting to manage patients with Covid-19. We summarise based on current evidence from around the world, what scientists say works and does not, from among the treatments currently in vogue in India.

Azithromycin: This must be the most widely prescribed and misused antibiotic in this pandemic. Azithromycin, as with all other antibiotics, does not work in viral infections. Antibiotics are only warranted in patients who have evidence of a secondary bacterial infection as some hospitalised patients will have in the later stages of their disease. Indiscriminate use (as was the case even before the pandemic) in the hope that they will prevent bacterial infection only worsens antibiotic resistance, to which India is a frequent contributor.

Blood Thinners: Hospitalised Covid-19 patients have been observed to have a very high incidence of blood clots. There is current global consensus that all hospitalised Covid-19 patients will benefit from blood thinners injected daily just under their skin (like insulin injections). Though there is sound mechanistic reasoning, randomised controlled trials are awaited.

BCG & other existing vaccines: While the world eagerly awaits a new and SARS-CoV-2-specific vaccine, the use of existing vaccines (BCG, Polio, MMR vaccines) in the hope they will work is inappropriate. Trials are under way to see if they will boost innate immunity. We know that BCG has already been given at birth to all Indians, and it does not seem to have helped keep our case numbers low.

Vitamin C: More vitamin C may have been consumed than oranges since Covid-19 began! It doesnt work.

Vitamin D: A large meta-analysis just released shows that Vitamin D does not protect against Covid-19.

Favipiravir: This is an oral antiviral drug which was fast tracked by the Indian Drug Controller but is not yet approved in the EU or US. Its use should be restricted to mild or moderate infections only. Available data to support its use is sparse but Indian trials have just been completed and the results are awaited.

Hydroxychloroquine sulphate (HCQS): We now have compelling data from multiple large clinical trials including WHOs SOLIDARITY and the UKs RECOVERY trials to categorically say: HCQS does not work. Even Donald Trump may have stopped taking it by now and so should you.

Ivermectin: This is an anti-parasitic drug widely prescribed in India and parts of South America to treat infections from worms. There is no evidence it has any role in Covid-19. It should not be used.

Miscellaneous cures: The state machinery has been used to distribute unproven herbal and Ayurvedic potions (Ukalo), homeopathic drops (Arsenicum album), and treatments peddled by god-men. Anecdotes and observations do not constitute scientific evidence. In the absence of evidence generated from rigorously vetted clinical trials, the distribution of these substances must be condemned. Pushing unproven and supposedly harmless treatments and distributing them to hundreds of thousands is not only disingenuous, but provides people false hope, and risks them lowering their guard. There are no magic pills to boost immunity to fix years of malnutrition, stunting, obesity, and chronically inflamed lungs.

Oseltamivir: This is an antiviral agent prescribed for tempering symptoms from the virus that causes influenza. It has no role in treating Covid-19 infection which is caused by a coronavirus.

Plasma: Our blood is composed of cells and plasma. Plasma from those who have recovered from Covid-19 carries naturally acquired antibodies, and, when transfused to critically ill patients with Covid-19, may help improve outcomes. This form of therapy is being used across the globe and trials to access its efficacy are under way.

Remdesivir: An intravenously administered antiviral medication, it has been shown to be effective in well-designed studies. It seems to shorten recovery time and hospital stay but does not reduce the chance of death. It is currently to be used only in hospitalised patients with severe disease.

Steroids: The only drug so far shown to have a striking impact on mortality is an old and inexpensive one. Current evidence shows that dexamethasone can reduce deaths by one-third in patients with severe Covid-19 infection who need oxygen therapy or ventilators. Their use should, however, be restricted to hospitalised patients. If they are given too soon in the course of an infection, or given to someone with only a mild infection, they could prevent the bodys own immune system from fighting the virus effectively.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Tocilizumab: This drug is an injection originally used in patients with rheumatoid arthritis. It is being widely used to counter the severe inflammation (cytokine storm) that occurs in some Covid-19 patients. Its use can increase the risk of bacterial infections, and it must therefore be used with caution, if at all, in carefully selected patients.

Zinc: This mineral is also commonly prescribed, despite there being no evidence that it is effective.

In conclusion, six months into the pandemic, we must therefore acknowledge four facts:

(Dr Zarir Udwadia is Consultant Chest Physician, PD Hinduja Hospital & Medical Research Centre, Mumbai. Dr Satchit Balsari is assistant professor in Emergency Medicine and in Global Health at Harvard Universitys medical and public health schools. )

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Here is the original post:

Explained: What works in Covid-19 treatment - The Indian Express

Laughter Really Is the Best Medicine: 6 Easy Ways to Add More Humor to Your Day – KCTV Kansas City

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } // } //val.instr = val.instr.replace(/[W_]+/g," "); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

Read more:

Laughter Really Is the Best Medicine: 6 Easy Ways to Add More Humor to Your Day - KCTV Kansas City

Impact Assessment of COVID-19 Outbreak on Nuclear Medicine & Radio Pharmaceuticals Market 2020 Global Industry Trends, Manufacturers, Growth,…

Global Nuclear Medicine & Radio Pharmaceuticals Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Nuclear Medicine & Radio Pharmaceuticals Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-&-radio-pharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147448#request_sample

Major Players:

GE HealthcareTriFoil ImagingBiosensors International Group, Ltd.EsaotePhilips HealthcareHitachiSiemens HealthcareCarestreamToshibaShimadzu

Global Nuclear Medicine & Radio Pharmaceuticals Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Diagnostic Medicine: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals.Therapeutic Medicine: Beta Emitters, Alpha Emitters, Brachytherapy Isotopes.

Segmentation by Application:

Diagnostic Applications: SPECT, PET.Therapeutic Applications: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Therapeutic Applications.

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/147448

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-&-radio-pharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147448#inquiry_before_buying

Table of Content:

The Global Nuclear Medicine & Radio Pharmaceuticals Market

Chapter 1: Nuclear Medicine & Radio Pharmaceuticals Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Nuclear Medicine & Radio Pharmaceuticals Market Competition by Manufacturers

Chapter 3: Nuclear Medicine & Radio Pharmaceuticals Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Nuclear Medicine & Radio Pharmaceuticals Market Effect Factors Analysis

Chapter 11: Nuclear Medicine & Radio Pharmaceuticals Market Forecast

Chapter 12: Conclusion of Nuclear Medicine & Radio Pharmaceuticals Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-&-radio-pharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147448#table_of_contents

Read this article:

Impact Assessment of COVID-19 Outbreak on Nuclear Medicine & Radio Pharmaceuticals Market 2020 Global Industry Trends, Manufacturers, Growth,...

Massive Demand in Artificial Intelligence in Medicine Market | Scope and Price Analysis of Top Manufacturers Profiles by 2027| Welltok, Inc., Intel…

HealthCare Intelligence Markets unravels its new study titled Artificial Intelligence in Medicine Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific, Japan, and India by considering different aspects such as type, size, as well as applications. SWOT and Porters five analysis have been used to analyse cost, prices, revenue, and end-users. Various aspects of businesses such as primary application areas, financial overview, and requirement of the industries have been mentioned to give a brief to the readers. This research study further offers mergers, acquisitions and product portfolio of the businesses.

Ask for sample copy of this [emailprotected]https://www.healthcareintelligencemarkets.com/request_sample.php?id=135746

Profiling Key players: Welltok, Inc., Intel Corporation, Nvidia Corporation, Google Inc., IBM Corporation, Microsoft Corporation, General Vision, Inc., Enlitic, Inc., BioXcel Corporation, and Berg Health.

Global Artificial Intelligence in Medicine Market Report Illuminates:

Ask for a discount on this [emailprotected]https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=135746

Table of Contents:

For more information ask our experts @https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=135746

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever-evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game-changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries. Our intelligence enables our clients to make decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact Us:Address: 90, State Office Center,90, State Street Suite 700,Albany, NY 12207Email:[emailprotected]Website:www.healthcareintelligencemarkets.comPhone:+1 (888) 616-2766

Originally posted here:

Massive Demand in Artificial Intelligence in Medicine Market | Scope and Price Analysis of Top Manufacturers Profiles by 2027| Welltok, Inc., Intel...